Last Updated: November 17, 2026

JIDEYTRO Drug Patent Profile

« Back to Dashboard


Which patents cover Jideytro, and what generic alternatives are available?

Jideytro is a drug marketed by Nuvalent and is included in one NDA. There are four patents protecting this drug.

The generic ingredient in JIDEYTRO is zidesamtinib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the zidesamtinib profile page.

DrugPatentWatch® Generic Entry Outlook for Jideytro

Jideytro will be eligible for patent challenges on July 22, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 30, 2042. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for JIDEYTRO?
  • What are the global sales for JIDEYTRO?
  • What is Average Wholesale Price for JIDEYTRO?
Summary for JIDEYTRO
US Patents:4
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
What excipients (inactive ingredients) are in JIDEYTRO?JIDEYTRO excipients list
DailyMed Link:JIDEYTRO at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for JIDEYTRO
Generic Entry Date for JIDEYTRO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:

TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for JIDEYTRO

JIDEYTRO is protected by four US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of JIDEYTRO is ⤷  Start Trial.

This potential generic entry date is based on patent 12,043,626.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nuvalent JIDEYTRO zidesamtinib TABLET;ORAL 220185-001 Jul 22, 2026 RX Yes No 12,054,498 ⤷  Start Trial ⤷  Start Trial
Nuvalent JIDEYTRO zidesamtinib TABLET;ORAL 220185-002 Jul 22, 2026 RX Yes Yes 12,054,498 ⤷  Start Trial ⤷  Start Trial
Nuvalent JIDEYTRO zidesamtinib TABLET;ORAL 220185-001 Jul 22, 2026 RX Yes No 12,043,626 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for JIDEYTRO

When does loss-of-exclusivity occur for JIDEYTRO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 22357554
Patent: SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS
Estimated Expiration: ⤷  Start Trial

Canada

Patent: 31813
Patent: FORMES SOLIDES, COMPOSITIONS PHARMACEUTIQUES ET PREPARATION DE COMPOSES ETHER MACROCYCLIQUES HETEROAROMATIQUES (SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS)
Estimated Expiration: ⤷  Start Trial

China

Patent: 8234725
Patent: 杂芳族大环醚化合物的固体形式、药物组合物及制备 (Solid forms of heteroaromatic macrocyclic ether compounds, pharmaceutical compositions and preparation)
Estimated Expiration: ⤷  Start Trial

European Patent Office

Patent: 08844
Patent: FORMES SOLIDES, COMPOSITIONS PHARMACEUTIQUES ET PRÉPARATION DE COMPOSÉS ÉTHER MACROCYCLIQUES HÉTÉROAROMATIQUES (SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS)
Estimated Expiration: ⤷  Start Trial

Israel

Patent: 1444
Patent: צורות מוצקות, תכשירים פרמצבטיים והכנת תרכובות אתר הטרואו-רומטיות מאקרוציקליות (Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds)
Estimated Expiration: ⤷  Start Trial

Japan

Patent: 24537795
Patent: ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製
Estimated Expiration: ⤷  Start Trial

Mexico

Patent: 24003738
Patent: FORMAS SOLIDAS, COMPOSICIONES FARMACEUTICAS Y PREPARACION DE COMPUESTOS DE ETER MACROCICLICO HETEROAROMATICO. (SOLID FORMS, PHARMACEUTICAL COMPOSITIONS AND PREPARATION OF HETEROAROMATIC MACROCYCLIC ETHER COMPOUNDS.)
Estimated Expiration: ⤷  Start Trial

South Korea

Patent: 240087788
Patent: 헤테로방향족 매크로사이클릭 에테르 화합물의 고체 형태, 약학 조성물 및 제조
Estimated Expiration: ⤷  Start Trial

Taiwan

Patent: 2320768
Patent: Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
Estimated Expiration: ⤷  Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JIDEYTRO around the world.

Country Patent Number Title Estimated Expiration
Australia 2021268664 ⤷  Start Trial
Brazil 112022022535 COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, MÉTODO DE TRATAMENTO DE CÂNCER, MÉTODO DE INIBIÇÃO SELETIVA, MÉTODO DE REDUÇÃO DE UM NÍVEL DE ROS1 OU ALK ⤷  Start Trial
Canada 3179700 AGENTS CHIMIOTHERAPEUTIQUES A BASE D'ETHERS MACROCYCLIQUES HETEROAROMATIQUES (HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS) ⤷  Start Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.